Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Beyond Air ( (XAIR) ) is now available.
On January 13, 2026, XTL Biopharmaceuticals announced a binding agreement to acquire Beyond Air’s 85% stake in NeuroNOS, a nitric oxide–focused biotech developing disease-modifying small-molecule therapeutics for Autism Spectrum Disorder and neuro-oncology, for consideration including a 19.9% equity stake in XTL, $1 million in cash and up to $32.5 million in development and commercial milestone payments. The deal elevates XTL into the fast-growing autism therapeutics market with NeuroNOS as its flagship platform, backed by scientific leadership from founder Prof. Haitham Amal and two Nobel laureates, and leverages NeuroNOS’s FDA Orphan Drug designations for Phelan-McDermid Syndrome and glioblastoma, while allowing Beyond Air to retain a significant strategic interest and potential upside as NeuroNOS advances with dedicated focus and funding.
The most recent analyst rating on (XAIR) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Beyond Air stock, see the XAIR Stock Forecast page.
Spark’s Take on XAIR Stock
According to Spark, TipRanks’ AI Analyst, XAIR is a Neutral.
The score is held down primarily by poor financial performance (large losses, high leverage, and weakening free cash flow). Technicals are mixed with improving momentum but an overbought RSI and price still below the 200-day average. Earnings call updates were a relative positive due to strong YoY growth and cost/burn improvements, but margins and leadership transition remain key risks.
To see Spark’s full report on XAIR stock, click here.
More about Beyond Air
Beyond Air is a commercial-stage medical device and biopharmaceutical company focused on harnessing endogenous and exogenous nitric oxide to treat respiratory illnesses, neurological disorders and solid tumors. Its first system, LungFit PH, has received both FDA approval and a CE Mark for treating hypoxic respiratory failure in term and near-term neonates, and the company is advancing additional LungFit systems in clinical trials for severe lung infections, while affiliate Beyond Cancer is developing ultra-high concentration nitric oxide therapies for solid tumors.
Average Trading Volume: 7,398,601
Technical Sentiment Signal: Sell
Current Market Cap: $15.06M
For an in-depth examination of XAIR stock, go to TipRanks’ Overview page.